Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.

Strahlenther Onkol · 2021 · PMC8547207 · PMID 34351453

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantp = 0.06so close (0.05 < p ≤ 0.1)

Comparing EBRT with seeds, we observed a borderline significant difference ( p = 0.06) regarding maximum late gastrointestinal and a significant difference regarding genitourinary toxicity ( p = 0.06 and p < 0.001, respectively).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.